The Utrogestan and hMG protocol in patients with polycystic ovarian syndrome undergoing controlled ovarian hyperstimulation during IVF/ICSI treatments-Reference-Cited by-同舟云学术

The Utrogestan and hMG protocol in patients with polycystic ovarian syndrome undergoing controlled ovarian hyperstimulation during IVF/ICSI treatments

Published:2016-07 Issue:28 Volume:95 Page:e4193
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Zhu Xiuxian,Ye Hongjuan,Fu Yonglun

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference38 articles.

1. The prevalence of polycystic ovary syndrome in a normal population according to the Rotterdam criteria versus revised criteria including anti-Mullerian hormone;Lauritsen;Hum Reprod,2014

2. Prevalence of polycystic ovary syndrome in women in China: a large community-based study;Li;Hum Reprod,2013

3. Is a GnRH antagonist protocol better in PCOS patients? A meta-analysis of RCTs;Lin;PLoS One,2014

4. Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT);Lainas;Hum Reprod,2010

5. Epidemiology, diagnosis, and management of polycystic ovary syndrome;Sirmans;Clin Epidemiol,2013

Cited by 49 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Progesterona para bloqueio hipofisário na indução da ovulação – possibilidades de emprego;Health Residencies Journal - HRJ;2024-02-27

2. Analysis of use of different rFSHs during IVF/ICSI-assisted conception in elderly population and effect of double trigger on clinical outcomes;The Journal of Maternal-Fetal & Neonatal Medicine;2024-01-02

3. The use of progestins to prevent the LH surge in IVF cycles;Handbook of Current and Novel Protocols for the Treatment of Infertility;2024

4. Duphaston as a suitable medication for women taking intracytoplasmic sperm injection to treat infertility;Reproductive and Developmental Medicine;2023-11-20

5. Cardiovascular adverse events of antineoplastic monoclonal antibodies among cancer patients: real-world evidence from a tertiary healthcare system;Cardio-Oncology;2023-09-25